patient stratification

Based on the results of the new studies, the Norwegian company is positioning its calprotectin test as an alternative to conventional ELISAs.

Chipscreen is developing a small molecule inhibitor of key serine-threonine kinases involved in tumor angiogenesis, cell mitosis, and microenvironment inflammation.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.